An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
Week of December 19, 2022
|
|
|
Shared Resources Survey
All MCC members are invited to in an important survey concerning our Shared Resources. The survey data will be used in the Cancer Center Support Grant (CCSG) renewal. Please make your voice heard. We need to hear from YOU!
|
|
|
Pan-Consortium Access to The Cancer Letter
The MCC Cancer Consortium now has full access to The Cancer Letter. See the attached welcome letter below for instructions on access.
|
|
|
Clinical Trials Office Director Transition
Dr. Sandip Patel has decided to step down from his current position as CTO Medical Director and concentrate on his oncology practice. Please join us in extending our tremendous thanks to Dr. Patel for his extraordinary leadership and vision during his tenure, during which he successfully lead the CTO through multiple challenges, which included fiscal issues and a global pandemic, to provide continued, uninterrupted patient access to our groundbreaking clinical trials. Kudos to Dr. Patel!
|
|
|
Director's Announcement: Invitation to Moores Cancer Center, Virtual Strategic Planning
MCC has partnered with UC San Diego’s Office of Operational Strategic Initiatives (OSI) to help define the future of research and academics at MCC. The plan will serve as our primary compass to guide not only decision-making for our research; training and education; and community outreach and engagement, but also the construction of our oncology services clinical strategic plan.
You are invited to participate in our visioning process by attending the following two virtual sessions led by our OSI partners to address our successes, opportunities, aspirations, and results (SOAR). We value your unique perspectives and will appreciate your time and feedback.
|
- Tuesday, January 10, 2023, 2:00 p.m. to 4:00 p.m. [Cancer Research Themes]
-
Wednesday, January 11, 2023, 10:00 a.m. to 12:00 p.m. [Keystone Concepts of Our Research and Academics] (i.e., clinical trials; community outreach and engagement; translation; education and training; research shared resources; industry collaborations; and workforce diversity)
|
We encourage you to attend both sessions, as they will emphasize distinct themes. If you have not yet received an Outlook/Zoom invitation, then please contact xvillanueva@health.ucsd.edu to be included in these strategic planning sessions.
|
|
|
Community Breast Cancer Awareness Event
Over the weekend of December 2-4, 2022, MCC, in coordination with Congregation Beth Am in San Diego North County and Sharsheret (a nationwide Jewish breast cancer organization that provides support for anyone facing breast cancer), held two panels to educate members of the San Diego community on the latest in breast cancer treatment, research, genetic risks (BRCA-1 and BRCA-2 mutations), and prevention.
|
|
|
|
A big thank you to Dr. Jennifer Matro, Dr. Jing Yang, and Dr. Julie Le, who all volunteered their time to participate on these important community education panels. Event participants also created 48 care packages (that included warm hats, fuzzy socks, playing cards, and activity books) for MCC breast cancer patients, which will be delivered to MCC next week to distribute to patients. Feedback received about not only event education, but also MCC physicians was extremely positive. Kudos to Dr. Matro, Dr. Yang, and Dr. Le for representing MCC!
|
|
|
Join the Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
Moderna’s mRNA cancer vaccine improves survival in phase IIb melanoma study—first observation of ef ficacy in an RCT
Read full article on page 9 of The Cancer Letter, volume 48 number 45.
Congressional bill focuses on cancer survivorship
Read full article on page 27 of The Cancer Letter, volume 48 number 45.
|
|
|
|
Cancer Biology and Signaling Seminar Series
Non-canonical IL-2 signaling promotes regulatory T cell function
Wednesday, December 21, 2022 from 12:00 p.m. to 1:00 p.m.
Zoom Link
Mark Ginsberg, M.D. Professor, Department of Medicine
UC San Diego, School of Medicine
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
2023 Cervical Cancer Awareness Summit
Thursday, January 19, 2023 from 10:00 a.m. to 12:00 p.m. PT
Join us virtually to learn from leaders in the field on the current and future state of cervical cancer treatment, research, and prevention.
|
| |
San Diego Colorectal Cancer Screening Roundtable
Thursday, February 22, 2023 from 10:00 a.m. to 12:00 p.m.
Join us for information on the current state of colorectal cancer screening in San Diego, upcoming changes in Medi-Cal, emerging screening tests, and how we can increase screening to get back on track.
This roundtable is designed for medical directors, clinicians, quality improvement staff, panel managers, project managers, and health center staff to hear and share best practices on improving colorectal cancer screenings in San Diego County.
|
|
|
CRTEC Beyond Academia: Exploring Careers in Science Policy
Tuesday, December 20, 2022 from 2:00 p.m. to 3:00 p.m.
|
|
|
Moores Cancer Center Speed Mentoring Workshop
Thursday, January 12, 2023 from 12:00 to 1:00 p.m.
This virtual workshop lasts for 1 hour, and each trainee (e.g., undergraduate student, graduate student, medical student, postdoc, resident, fellow, or junior faculty member) will have the opportunity to speak with three mentors. Speed mentoring is an efficient way to get sound advice from a variety of perspectives in a short amount of time!
|
|
|
Student Volunteers Available
Cancer Research, Training, and Education Coordination (CRTEC) has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. (aspilkin@health.ucsd.edu), if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, and research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Faculty Seed Grant Proposals for 2023-2024 Award Year
Maximum funding $75,000 for 2023-2024
The University of California (UC) Cancer Research Coordinating Committee (CRCC) is a systemwide, faculty-directed cancer research program that provides competitive intramural research awards for topics in any discipline that address any aspect of cancer, which include its origins, detection, prevention, and cure. The UC CRCC provides 1-year seed grants to faculty on the 10 UC campuses, with the expectation that the most promising endeavors will become competitive for larger, long-term grants from other funding sources. Awards are made in two categories: New Assistant Professor (NAP) and Regular (REG).
Required LOI Deadline: January 24, 2023
Application Deadline: April 13, 2023
|
| |
Advancing Head and Neck Cancer Early Detection Research (AHEAD)
Maximum funding $500,000 direct costs/year for 5 years
The purpose of this Funding Opportunity Announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that target early detection of HNC by (1) applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions and (2) identifying prognostic signatures on the transformation from premalignant to malignant lesions.
Deadline: January 27, 2023 at 5:00 p.m.
|
|
|
The UC Pancreatic Cancer Consortium Plans to Submit a SPORE Proposal to the National Cancer Institute (NCI) in May, 2023
As you probably know, SPORE project proposals are distinctly different from either R01 or U01 research mechanisms, in that they must be translational. In every SPORE project, the development of new cancer-relevant interventions should include both a laboratory component and a human application (see RFP linked below for further detail). Project budgets are expected on the order of $200,000–$250,000/year for 5 years, although projects on early detection, prevention, or population science can request up to an additional $120,000/year.
Deadline: Tuesday, January 31, 2023
Questions? Contact Kurt Giles, D.Phil. at kurt.giles@ucsf.edu
|
|
|
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and may not exceed $750,000 in direct costs per year for the UH3 phase
Through this FOA, the NCI intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Deadline: February 14, 2023 by 5:00 p.m. and June 14, 2023 by 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects – Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners: October 2022 - November 2022
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
University of California, Hematologic Malignancies Consortium (UCHMC) Request for Proposals (RFP)
The UCHMC is requesting submission of proposals within two potential areas of funding: RFP A and RFP B.
All applications are to be submitted via email as a single PDF to Jesika Reiner, MPH, MBA at JReiner@uchmc.org and Mwieduwilt@uchmc.org.
RFP A: UCHMC Funds for Junior Faculty and Trainee Competitive Seed Grants
This funding will support single or multi-center pilot clinical trials, translational lab-based projects, or retrospective projects, which may ultimately grow into multicenter UCHMC interventional clinical trials. Funding also may be applied for fellowship support to conduct clinical trials research with the UCHMC. Funding also may support correlative research that may or may not be associated with an existing UCHMC trial yet with translational aims that possess potential for development into a UCHMC trial. The award amount will be determined by the UCHMC Steering Committee, but individual requests should not exceed $40,000.
RFP B: UCHMC Funds for Clinical Trials Support
This funding will support underfunded yet promising clinical trials and correlative research projects associated with an existing clinical trials or other multi-center projects that hold promise for development into larger multicenter UCHMC clinical trials. These awards will range from $100,000 to $150,000 in a given award period, with the number of projects awarded based on number of applications and scientific need as determined by the UCHMC Steering Committee, which reserves the right to award a larger total funds as they see fit.
Applicants may apply for both RFPs but will be awarded only one as a lead investigator. An applicant can be a collaborator on more than one application in a given award period.
Application Format
|
- Cover Page
- Project title
- Project investigators (Lead and Sub-Investigators) and affiliations
- Project start date
- Project end date
- Concurrent UCHMC applications of Lead Investigator
- Applicant contact
- Project Information
- Brief project description with hypothesis(es)
- Detailed project description with supporting preclinical and/or clinical data, rationale, study design, and statistical plan, as appropriate
- Budget
- Budget justification
- Other sources of funding
-
Statement of commitment to develop results into UCHMC interventional clinical trials when possible
- Attachments
- CVs of investigators associated with the proposed project
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
| Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54 Clinical Trial Optional)
Budgets are limited to $2 million in direct costs per year for partnerships of two institutions and $2.5 million in direct costs per year for partnerships of three institutions; maximum duration 5 years.
Deadline: January 6, 2023 at 5:00 p.m. PT; LOI due 30 days prior
|
|
|
Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20 Clinical Trial Not Allowed)
The combined budget for ISUPS and CC cannot exceed $375,000 in direct costs per year; maximum duration 4 years.
Deadline: January 6, 2023 at 5:00 p.m. PT; LOI due 30 days prior
|
|
|
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Liquid Biopsy Research Laboratories (U01 and U24)
U01 Award: $600,000 direct costs per year for 5 years
U24 Award: $450,000 direct costs per year for 5 years
Deadline: January 10, 2023 at 4:00 p.m. ET
|
| NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required)
NCI intends to commit $1.5M in FY 2024 to fund one award; $2M is expected to be allocated per year in subsequent years for the CCC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| NCI Cancer Screening Research Network: Statistics and Data Management Center (UG1 Clinical Trial Required)
NCI intends to commit $1M in FY 2024 to fund one award. $2M is expected to be allocated per year in subsequent years for the SDMC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required)
NCI intends to commit $8M in FY 2024 to fund 10-15 awards. $9M is expected to be allocated per year in subsequent years for ACCESS Hubs; requested budget must not exceed $750,000 in direct costs per year; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years; NIH R01 standard due dates apply.
Deadline: February 5, 2023 at 5:00 p.m.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
Limited $500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT DRCC will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
|
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested. The maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
| |
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Cancer Therapeutics Training (CT2) Program at Moores Cancer Center OPEN POSITIONS AVAILABLE
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure, Documents, and Requirements
|
-
Complete CT2 program application (form available to download from the website above)
- Curriculum vitae
- One-page personal statement
- Proof of U.S. citizenship or permanent resident status
- Three letters of recommendation (one from an identified mentor)
- Ph.D. or M.D. degree
|
For more information or to apply, please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu
See WEBSITE for more details about the CT2 program.
Deadline: January 15, 2023
|
| |
Urology for Social Responsibility
Saturday, January 14, 2023 from 7:30 a.m. to 5:30 p.m. Reception to follow.
Sunday, January 15, 2023 from 7:30 a.m. to 5:30 p.m.
Specific themes and topics to be discussed are the following:
|
|
|
- Global Volunteerism for Humanitarian Aid
- Climate Change
-
Sustainability in the Operating Room
|
| -
Health Rights for All (Abortion, LGBTQIA, Underserved, Incarcerated)
- Health Access for All (Healthcare Reform, Pharma Reform)
- Basic Human Rights (Food and Shelter, Violence [Gun, Domestic, Child])
|
| - Diversity, Equity and Inclusion in Urology
- Gender Equity in Urology
-
Wellness and Burnout in Urology
|
|
|
Saturday, January 28, 2023
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
| Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Big Data Training for Cancer Research - BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration and tuition! The workshop will be held on-site at Purdue University, in West Lafayette, IN. There will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
Newly Opened Clinical Trials
|
|
|
CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HAWBRT) Plus Memantine for 515 Brain Metastases
PI: Hattangadi-Gluth, J
NCT: NCT03550391
|
| |
|
|
TAK-573-1001: An Open-Label, Dose-Escalation Phase 1 Study to Evaluate the Safety, Tolerability, pharmacokinetics, and Pharmacodynamics of TAK573 in Adult Patients with Metastatic Solid Tumors
PI: Daniels, G
NCT: NCT04157517
|
| | |
|
BAY 1841788 / 21516: Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer Using An External Control Arm (ARASEC)
PI: McKay, R
NCT: NCT04736199
|
| |
|
|
| Congratulations to Taylor Nonato for being recognized as CTO Staff of the Month for November, 2022!
The Clinical Trials Office and Genitourinary (GU) Team is recognizing Taylor for consistently going above and beyond as an all around team player while always maintaining a positive attitude. Taylor is reliable, enthusiastic, and has made a huge difference on the GU Team, despite the many obstacles the team has faced in the last few months. Taylor is incredibly hardworking and is someone the GU team can count on!
|
|
|
SHARED RESOURCE SPOTLIGHT
|
| |
Biorepository and Tissue Technology Shared Resource (BTTSR)
The BTTSR is a College of American Pathologists (CAP)-accredited resource that constitutes an essential component of the MCC infrastructure that supports translational studies. The BTTSR is founded on a well-established model that integrates tissue procurement, processing, storage, and multimodal (i.e., histologic, immunohistochemical, and molecular) analyses with traditional epidemiologic, clinicopathologic, and outcome parameters, through a highly evolved bioinformatics system. The BTTSR supports researchers (i.e., MCC, C3, and others) by providing annotated human liquid and solid bio-specimens, and state-of-the-art histological processing, interpretation, and histopathological analysis of samples. The BTTSR provides MCC investigators and their scientific partners with annotated biospecimens from humans and experimental animals.
|
|
|
Biorepository (BR) Services
|
- TISSUE ACQUISITION
- Patient consenting services
- Prospective tissue procurement and processing
- SOP development and training
- Clinical trials support
- TISSUE STORAGE
-
Tissue storage in ultra-low and LN2freezers
- Custom storage as needed
- TISSUE DISTRIBUTION AND INVENTORY
- Blood derivatives: buffy coat, plasma, serum, PBMCs
- Fresh frozen tissue
- Viable freeze protocols
- Formalin fixed paraffin embedded tissue
- Formalin fixed paraffin embedded tissue and PDX models
- NEW: NUCLEIC ACID EXTRACTION AND QA FROM ALL BIOSPECIMEN TYPES
|
|
Tissue Technology (TT) Services
|
- ROUTINE HISTOLOGY
- FFPE/Frozen section
- Routine H&E staining
- Special stains
- Bone decalcification
- IMMUNOHISTOCHEMISTRY/IMMUNOFLUORSECENCE
- Single and multiplexing
- Whole slide scanning / digital pathology
- Brightfield
- Fluorescence
-
TISSUE MICROARRAY (TMA) DESIGN AND CONSTRUCTION
- PATHOLOGY CONSULTATION
- NEW: SPATIAL BIOLOGY: PHENOCYCLER FUSION (FORMER CODEX)
|
|
|
-
Tamaki N, Ahlholm N, Luukkonen PK, Porthan K, Sharpton SR, Ajmera V, Kono Y (ZY), Dave S, Ahmed A, Sundaram V, Wilkinson MJ, Patton H, Gupta H, Cervantes V, Hernandez C, Lopez SJ, Loomba R, Baumgartner A, Richards L, Arkkila PE, Nemes K, Isoniemi H, Yki-Järvinen H, Loomba R (CCP). Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest. 2022 NOV 01; 132(21).
- Kwon Y, Mehta S, Clark M, Walters G, Zhong Y, Lee HN, Sunahara RK, Zhang J (CBS). Non-canonical β-adrenergic activation of ERK at endosomes. Nature. 2022 NOV 01; 611(7934):173-179.
-
Gupta S (CCP), Earles A, Bustamante R, Patterson OV, Gawron AJ, Kaltenbach TR, Yassin H, Lamm M, Shah SC (CCP), Saini SD, Fisher DA, Martinez ME (CCP), Messer K (CCP), Demb J, Liu L. Adenoma detection rate and clinical characteristics influence advanced neoplasia risk after colorectal polypectomy. Clin Gastroenterol Hepatol. 2022 OCT 18.
-
Bootsma M, McKay RR (STT), Emamekhoo H, Bade RM, Schehr JL, Mannino MC, Singh A, Wolfe SK, Schultz ZD, Sperger J, Xie W, Signoretti S, Kyriakopoulos CE, Kosoff D, Abel EJ, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Bassetti M, Floberg J, Yu M, Sethakorn N, Sharifi M, et al. Longitudinal molecular profiling of circulating tumor cells in metastatic renal cell carcinoma. J Clin Oncol. 2022 NOV 01; 40(31):3633-3641.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to the newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie, at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the Moores Cancer Center newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the website. Please provide us with the data we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|